A5009256008- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Neuroendocrine Tumor Research Advances
- Cancer survivorship and care
- Neuroblastoma Research and Treatments
- Neutropenia and Cancer Infections
- Cancer Immunotherapy and Biomarkers
- Prostate Cancer Treatment and Research
- Nausea and vomiting management
- Palliative Care and End-of-Life Issues
- Renal cell carcinoma treatment
- Childhood Cancer Survivors' Quality of Life
- Chemotherapy-related skin toxicity
- Multiple and Secondary Primary Cancers
- Gastric Cancer Management and Outcomes
- Hepatocellular Carcinoma Treatment and Prognosis
- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Economic and Financial Impacts of Cancer
- Oral health in cancer treatment
- Pathogenesis and Treatment of Hiccups
- Cancer therapeutics and mechanisms
- Renal and related cancers
University of Turin
2025
Fondazione IRCCS Istituto Nazionale dei Tumori
2024
Azienda Ospedaliera Universitaria Pisana
2014-2023
Creative Commons
2023
University of Brescia
2023
University of Pisa
1995-2022
National Health Service
2021
Polo d’Innovazione di Genomica
2014-2020
Samara University
2017
Associazione Italiana Di Oncologia Medica
2014-2016
Abstract Purpose: Selecting patients according to key genetic characteristics may help tailor chemotherapy and optimize the treatment in non–small cell lung cancer (NSCLC). Polymorphisms at xeroderma pigmentosum group D (XPD), excision repair cross-complementing 1 (ERCC1), cytidine deaminase (CDA) genes have been associated with alterations enzymatic activity change sensitivity widely used cisplatin-gemcitabine regimen. Experimental Design: Analyses of CDA, XPD, ERCC1 polymorphisms were done...
Diarrhoea is defined as the frequent passage of loose stools with urgency (or more than normal for individual). Objectively defined, it three unformed in 24 hours [1]. Often patient's definition diarrhoea varies and needs to be clarified by medical staff, through an adequate assessment.
Abstract Patients with melanoma brain metastases have a poor prognosis and historically been excluded from clinical trials. The Expanded Access Program (EAP) provided an opportunity to evaluate the feasibility of ipilimumab (3 mg/kg every 3 weeks for four doses) in patients stage (unresectable) or 4 asymptomatic metastases, who had failed did not tolerate previous treatments no other therapeutic option available. Tumor assessments were conducted at baseline week 12 using immune-related...
Patients treated with platinum compounds are subject to hypersensitivity reactions. Our study has highlighted the reactions related oxaliplatin (OHP) infusion. One hundred and twenty-four patients affected by advanced colorectal cancer were different schedules containing OHP, at Institute of Haematology Medical Oncology 'L. A. Seragnoli' Bologna Division Livorno Hospital. Seventeen (13%) showed after a few minutes from start OHP Usually, these seen 2–17 exposures (Mean±s.e.: 9.4±1.07). No...
<b><i>Purpose:</i></b> The role of chemotherapy in low-/intermediate-grade neuroendocrine tumors (NETs) is still debated. We present the results an Italian multicenter retrospective study evaluating activity and toxicity oxaliplatin-based patients with advanced NETs. <b><i>Methods:</i></b> Clinical records from 5 referral centers were reviewed. Disease control rate (DCR) corresponding to PR + SD (partial response stable disease) at 6 months,...
Abstract Purpose: The aims of the present study were to evaluate clinical activity and pharmacodynamic profile novel schedule a single i.v. standard dose cyclophosphamide (CTX) immediately followed by an oral metronomic CTX regimen with celecoxib (CXB) dexamethasone (DEX) in advanced hormone-refractory prostate cancer patients. Experimental Design: Twenty-eight patients (68% docetaxel-resistant) received 500 mg/m2 bolus on day 1 and, from 2, 50 mg/day p.o. plus 200 mg/twice CXB DEX until...
Background/Objectives: Cancer pain is prevalent across all stages of the disease, significantly impacting patients’ lives. Despite availability guidelines, its assessment and management remain suboptimal in many clinical settings. This study aimed to explore how healthcare professionals Italy assess manage cancer pain, identifying gaps educational needs improve adherence best practices. Methods: A multidisciplinary Scientific Board designed an online survey comprising 28 items addressing...
Long-acting depot forms of somatostatin analogs administered by intramuscular injections are now available for the treatment neuroendocrine tumors (NETs). In present study, we investigated efficacy and tolerability a slow-release form lanreotide in patients with advanced NETs. From July 1996 to January 1999, 25 NETs (12 carcinoids, 13 endocrine pancreatic tumors) were enrolled study. Thirteen pretreated subcutaneous octreotide, chemotherapy, or hepatic metastasis alcoholization. All had...
The BRAF K601E mutation occurs in 5% of patients with melanoma, and is the third most common type mutation. However, treatment mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors only approved V600-positive K601E-mutated melanoma do not have access to such drugs. A female patient was diagnosed high tumor burden metastatic harboring After chemotherapy failure, she underwent compassionate trametinib. Trametinib showed good activity efficacy, 48% shrinkage a lymphadenopathy...
BACKGROUND Docetaxel plus prednisone is currently the standard first‐line treatment in metastatic castration‐resistant prostate cancer (mCRPC). The aim of this study was to assess clinical activity and pharmacodynamic/pharmacogenetic profile docetaxel combination with metronomic cyclophosphamide mCRPC patients. METHODS Forty‐one chemotherapy‐naive patients received (60 mg/m 2 intravenously every 3 weeks up 12 cycles) and, from day 2, 10 mg/day, celecoxib 400 50 continuously. Plasma VEGF bFGF...
The triple drug combination consisting of irinotecan, oxaliplatin and 5-fluorouracil (FOLFOXIRI) has demonstrated higher activity efficacy compared to the doublet FOLFIRI. 5-Fluorouracil could be substituted in FOLFOXIRI regimen by capecitabine, an oral fluoropyrimidine with similar efficacy. Recently, a dose-finding trial feasibility capecitabine (XELOXIRI) established their recommended doses. aim this study was evaluate XELOXIRI. A total 36 patients unresectable metastatic colorectal...
Abstract BACKGROUND The objective of this study was to evaluate the efficacy and toxicity gemcitabine plus epirubicin in previously untreated patients with advanced urothelial carcinoma who were not eligible for cisplatin‐based regimens. METHODS Patients at least one following characteristics eligible: impaired renal function (creatinine clearance < 60 mL per minute), an Eastern Cooperative Oncology Group performance status (PS) ≥ 2, age 75 years. treatment included 70 mg/m 2 as...
Background: To date, no biomarkers are effective in predicting the risk of developing immune-related adverse events (irAEs) patients treated with immune checkpoint inhibitors (ICIs). This study aims to evaluate association between basal absolute eosinophil count (AEC) and irAEs during treatment ICIs for solid tumors. Methods: We retrospectively evaluated 168 metastatic melanoma (mM), renal cell carcinoma (mRCC), non-small lung cancer (mNSCLC) receiving at our medical oncology unit. By...